Reported about 12 hours ago
Eli Lilly experienced a significant profit increase in the third quarter, driven by strong demand for its weight-loss drugs, particularly Mounjaro and Zepbound. Mounjaro's revenue more than doubled, reaching $6.52 billion, contributing to an overall 54% revenue growth that surpassed Wall Street expectations. The company also raised its full-year revenue and earnings forecasts, while preparing to launch a new weight-loss pill that may enhance demand further.
Source: YAHOO